Archives: 2021-04-30

Covid-19: How can we keep the world’s doctors safe? An important paper by Fiona Godlee on The BMJ

The world’s doctors have been at the forefront of the pandemic response. Already overstretched by workforce shortages, they have carried exhaustion, uncertainty, and risk, redeploying to unfamiliar specialties, learning at speed, and adopting different ways of working and new technology, while all the time fearing for their patients, their families, and themselves. For many there has

Read More


In JAMA US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S J&J Vaccination, March 2 to April 21, 2021

Cerebral venous sinus thrombosis (CVST) with thrombocytopenia, a rare and serious condition, has been described in Europe following receipt of the ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca), which uses a chimpanzee adenoviral vector. A mechanism similar to autoimmune heparin-induced thrombocytopenia (HIT) has been proposed. In the US, the Ad26.COV2.S COVID-19 vaccine (Janssen/Johnson & Johnson), which uses a

Read More


Extracellular Vesicles from Human Adipose-Derived Mesenchymal Stem Cells: A Review of Common Cargos published in Stem Cell Reviews and Reports

In recent years, the interest in adipose tissue mesenchymal cell–derived extracellular vesicles (AT-MSC-EVs) has increasingly grown. Numerous articles support the potential of human AT-MSC-EVs as a new therapeutic option for treatment of diverse diseases in the musculoskeletal and cardiovascular systems, kidney, skin, and immune system, among others. This approach makes use of the molecules transported

Read More


Francis Crick Institute @The Crick researchers uncover a naturally occurring molecule that can help coronavirus escape antibodies

Researchers have found that a natural molecule can effectively block the binding of a subset of human antibodies to SARS-CoV-2. The discovery may help explain why some COVID-19 patients can become severely ill despite having high levels of antibodies against the virus. In their research, published in Science Advances today (22 April 2021), teams from the Francis

Read More


Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study published on The Lancet Haematology

Chimeric antigen receptor (CAR) T-cell therapy can induce side-effects such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS), which often require intensive care unit admission. The aim of the study, published in The Lancet Haematology was to describe management of critically ill CAR T-cell recipients in intensive care. An international, multicentre, observational

Read More


Successful treatment of vaccine‐induced prothrombotic immune thrombocytopenia (VIPIT) with early steroids and IVIG.

Cases of unusual thrombosis and thrombocytopenia after administration of the ChAdOx1 nCoV‐19 vaccine (AstraZeneca) have been reported. The term vaccine‐induced prothrombotic immune thrombocytopenia (VIPIT) was coined to reflect this new phenomenon.  In vitro experiments with VIPIT patient sera indicated that high dose intravenous immunoglobulins (IVIG) competitively inhibit the platelet activating properties of ChAdOx1 nCoV‐19 vaccine induced

Read More


Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant identified in California

In a paper recently published on Cell, an emerging SARS-CoV-2 variant was identified by viral whole-genome sequencing of 2,172 nasal/nasopharyngeal swab samples from 44 counties in California, a state in the Western United States. Named B.1.427/B.1.429 to denote its 2 lineages, the variant emerged in May 2020 and increased from 0% to >50% of sequenced

Read More